Adverse Outcomes Up for Vaginal Birth After Previous C-Section

Share this content:
Adverse Outcomes Up for Vaginal Birth After Previous C-Section
Adverse Outcomes Up for Vaginal Birth After Previous C-Section

MONDAY, May 7, 2018 (HealthDay News) -- The rates of severe maternal and neonatal morbidity and mortality are elevated with attempted vaginal delivery after single prior cesarean delivery, according to a study published in the May 7 issue of CMAJ, the journal of the Canadian Medical Association.

Carmen B. Young, M.D., from the University of Alberta in Edmonton, Canada, and colleagues compared maternal and infant outcomes after attempted vaginal birth after cesarean delivery versus elective repeat cesarean delivery.

The researchers found that there were low absolute rates of severe maternal morbidity and mortality, but the rates were significantly higher after attempted vaginal birth versus after elective repeat cesarean delivery (10.7 versus 5.65 per 1,000 deliveries; adjusted rate ratio, 1.96; 95 percent confidence interval, 1.76 to 2.19). Small adjusted rate differences were seen in severe maternal morbidity and mortality (5.42 per 1,000 deliveries) and serious neonatal morbidity and mortality (7.09 per 1,000 deliveries). A temporal worsening was seen for the correlation between vaginal birth after cesarean delivery and serious neonatal morbidity and mortality (adjusted rate ratio, 0.94; 95 percent confidence interval, 0.77 to 1.15 in 2003 to 2005; adjusted rate ratio, 2.07; 95 percent confidence interval, 1.83 to 2.35 in 2012 to 2014).

"Temporal worsening of infant outcomes after attempted vaginal birth after cesarean delivery highlights the need for greater care in selecting candidates, and more careful monitoring of labor and delivery," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »